Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT®)

Nicoletta Urbano, Stefano Papi, Mauro Ginanneschi, Rita De Santis, Silvia Pace, Ragnar Lindstedt, Liliana Ferrari, Sunju Choi, Giovanni Paganelli, Marco Chinol

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: A novel biotin-DOTA conjugate (r-BHD: reduced biotinamidohexylamine-DOTA) was investigated in order to provide an efficient pretargeted antibody-guided radioimmunotherapy (PAGRIT®) application. Preclinical and clinical results are described. Methods: 90Y and 177Lu were used to label r-BHD. The effect of pH and a wide range of specific activities were studied. Radiolabelled r-BHD was tested for affinity towards avidin and for stability in saline or in human serum with and without ascorbic acid. Pharmacokinetic data were collected and organ biodistribution evaluated in a tumour-bearing pretargeted animal model. A pilot study was performed in a metastatic melanoma patient and dosimetry was estimated. Results: High radiochemical purity (>99%) was routinely achieved with 90Y or 177Lu in sodium acetate buffer (1.0 M, pH 5.0) at a specific activity of 2.6 MBq/nmol. Both 90Y- and 177Lu-r-BHD were also prepared at higher specific activities. Radiolabelled r-BHD was stable up to 96 h in human serum and saline with the addition of ascorbic acid. The structural modifications proposed for the r-BHD stabilised it against enzymatic degradation while retaining high binding affinity for avidin. Renal clearance appeared to be the main route of excretion in animals, and high tumour uptake was observed in the pretargeted animals. The patient study showed a total body clearance of ∼85% in 24 h, with a kidney absorbed dose of 1.5 mGy/MBq. Tumour uptake was rapid and the calculated dose to a 10-mm tumour lesion was ∼12 mGy/MBq. Conclusion: These results indicate that the new biotin-DOTA conjugate may be a suitable candidate for pretargeting trials.

Original languageEnglish
Pages (from-to)68-77
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Radioimmunotherapy
Avidin
Antibodies
Ascorbic Acid
Neoplasms
Kidney
Sodium Acetate
Serum
Melanoma
Buffers
Animal Models
Pharmacokinetics
DOTA-biotin

Keywords

  • Lutetium-177
  • Pretargeting
  • Radiolabelled biotin
  • Tumour therapy
  • Yttrium-90

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT®). / Urbano, Nicoletta; Papi, Stefano; Ginanneschi, Mauro; De Santis, Rita; Pace, Silvia; Lindstedt, Ragnar; Ferrari, Liliana; Choi, Sunju; Paganelli, Giovanni; Chinol, Marco.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, No. 1, 01.2007, p. 68-77.

Research output: Contribution to journalArticle

Urbano, Nicoletta ; Papi, Stefano ; Ginanneschi, Mauro ; De Santis, Rita ; Pace, Silvia ; Lindstedt, Ragnar ; Ferrari, Liliana ; Choi, Sunju ; Paganelli, Giovanni ; Chinol, Marco. / Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT®). In: European Journal of Nuclear Medicine and Molecular Imaging. 2007 ; Vol. 34, No. 1. pp. 68-77.
@article{ac44c7646b7245dfbfa4b98c7bdb3216,
title = "Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT{\circledR})",
abstract = "Purpose: A novel biotin-DOTA conjugate (r-BHD: reduced biotinamidohexylamine-DOTA) was investigated in order to provide an efficient pretargeted antibody-guided radioimmunotherapy (PAGRIT{\circledR}) application. Preclinical and clinical results are described. Methods: 90Y and 177Lu were used to label r-BHD. The effect of pH and a wide range of specific activities were studied. Radiolabelled r-BHD was tested for affinity towards avidin and for stability in saline or in human serum with and without ascorbic acid. Pharmacokinetic data were collected and organ biodistribution evaluated in a tumour-bearing pretargeted animal model. A pilot study was performed in a metastatic melanoma patient and dosimetry was estimated. Results: High radiochemical purity (>99{\%}) was routinely achieved with 90Y or 177Lu in sodium acetate buffer (1.0 M, pH 5.0) at a specific activity of 2.6 MBq/nmol. Both 90Y- and 177Lu-r-BHD were also prepared at higher specific activities. Radiolabelled r-BHD was stable up to 96 h in human serum and saline with the addition of ascorbic acid. The structural modifications proposed for the r-BHD stabilised it against enzymatic degradation while retaining high binding affinity for avidin. Renal clearance appeared to be the main route of excretion in animals, and high tumour uptake was observed in the pretargeted animals. The patient study showed a total body clearance of ∼85{\%} in 24 h, with a kidney absorbed dose of 1.5 mGy/MBq. Tumour uptake was rapid and the calculated dose to a 10-mm tumour lesion was ∼12 mGy/MBq. Conclusion: These results indicate that the new biotin-DOTA conjugate may be a suitable candidate for pretargeting trials.",
keywords = "Lutetium-177, Pretargeting, Radiolabelled biotin, Tumour therapy, Yttrium-90",
author = "Nicoletta Urbano and Stefano Papi and Mauro Ginanneschi and {De Santis}, Rita and Silvia Pace and Ragnar Lindstedt and Liliana Ferrari and Sunju Choi and Giovanni Paganelli and Marco Chinol",
year = "2007",
month = "1",
doi = "10.1007/s00259-006-0124-4",
language = "English",
volume = "34",
pages = "68--77",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "1",

}

TY - JOUR

T1 - Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT®)

AU - Urbano, Nicoletta

AU - Papi, Stefano

AU - Ginanneschi, Mauro

AU - De Santis, Rita

AU - Pace, Silvia

AU - Lindstedt, Ragnar

AU - Ferrari, Liliana

AU - Choi, Sunju

AU - Paganelli, Giovanni

AU - Chinol, Marco

PY - 2007/1

Y1 - 2007/1

N2 - Purpose: A novel biotin-DOTA conjugate (r-BHD: reduced biotinamidohexylamine-DOTA) was investigated in order to provide an efficient pretargeted antibody-guided radioimmunotherapy (PAGRIT®) application. Preclinical and clinical results are described. Methods: 90Y and 177Lu were used to label r-BHD. The effect of pH and a wide range of specific activities were studied. Radiolabelled r-BHD was tested for affinity towards avidin and for stability in saline or in human serum with and without ascorbic acid. Pharmacokinetic data were collected and organ biodistribution evaluated in a tumour-bearing pretargeted animal model. A pilot study was performed in a metastatic melanoma patient and dosimetry was estimated. Results: High radiochemical purity (>99%) was routinely achieved with 90Y or 177Lu in sodium acetate buffer (1.0 M, pH 5.0) at a specific activity of 2.6 MBq/nmol. Both 90Y- and 177Lu-r-BHD were also prepared at higher specific activities. Radiolabelled r-BHD was stable up to 96 h in human serum and saline with the addition of ascorbic acid. The structural modifications proposed for the r-BHD stabilised it against enzymatic degradation while retaining high binding affinity for avidin. Renal clearance appeared to be the main route of excretion in animals, and high tumour uptake was observed in the pretargeted animals. The patient study showed a total body clearance of ∼85% in 24 h, with a kidney absorbed dose of 1.5 mGy/MBq. Tumour uptake was rapid and the calculated dose to a 10-mm tumour lesion was ∼12 mGy/MBq. Conclusion: These results indicate that the new biotin-DOTA conjugate may be a suitable candidate for pretargeting trials.

AB - Purpose: A novel biotin-DOTA conjugate (r-BHD: reduced biotinamidohexylamine-DOTA) was investigated in order to provide an efficient pretargeted antibody-guided radioimmunotherapy (PAGRIT®) application. Preclinical and clinical results are described. Methods: 90Y and 177Lu were used to label r-BHD. The effect of pH and a wide range of specific activities were studied. Radiolabelled r-BHD was tested for affinity towards avidin and for stability in saline or in human serum with and without ascorbic acid. Pharmacokinetic data were collected and organ biodistribution evaluated in a tumour-bearing pretargeted animal model. A pilot study was performed in a metastatic melanoma patient and dosimetry was estimated. Results: High radiochemical purity (>99%) was routinely achieved with 90Y or 177Lu in sodium acetate buffer (1.0 M, pH 5.0) at a specific activity of 2.6 MBq/nmol. Both 90Y- and 177Lu-r-BHD were also prepared at higher specific activities. Radiolabelled r-BHD was stable up to 96 h in human serum and saline with the addition of ascorbic acid. The structural modifications proposed for the r-BHD stabilised it against enzymatic degradation while retaining high binding affinity for avidin. Renal clearance appeared to be the main route of excretion in animals, and high tumour uptake was observed in the pretargeted animals. The patient study showed a total body clearance of ∼85% in 24 h, with a kidney absorbed dose of 1.5 mGy/MBq. Tumour uptake was rapid and the calculated dose to a 10-mm tumour lesion was ∼12 mGy/MBq. Conclusion: These results indicate that the new biotin-DOTA conjugate may be a suitable candidate for pretargeting trials.

KW - Lutetium-177

KW - Pretargeting

KW - Radiolabelled biotin

KW - Tumour therapy

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=33845365954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845365954&partnerID=8YFLogxK

U2 - 10.1007/s00259-006-0124-4

DO - 10.1007/s00259-006-0124-4

M3 - Article

C2 - 16755333

AN - SCOPUS:33845365954

VL - 34

SP - 68

EP - 77

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 1

ER -